US4682645A
(en)
*
|
1986-03-03 |
1987-07-28 |
Olin Corporation |
Control system for electromagnetic casting of metals
|
US4963681A
(en)
*
|
1987-07-06 |
1990-10-16 |
Norwich Eaton Pharmaceuticals, Inc. |
Process for synthesis of aminomethylene phosphonoalkylphosphinates
|
US5212164A
(en)
*
|
1988-08-29 |
1993-05-18 |
E. R. Squibb & Sons, Inc. |
Phosphorus-containing squalene synthetase inhibitors
|
EP0356866A3
(fr)
*
|
1988-08-29 |
1991-03-27 |
E.R. SQUIBB & SONS, INC. |
Inhibiteurs phosphorés de la synthétase du squalène et procédé
|
CA2007643A1
(fr)
*
|
1989-02-01 |
1990-08-01 |
Donald S. Karanewsky |
Combinaison d'un inhibiteur de hmg coa et d'un inhibiteur de squalene synthetase et methode pour abaisser le taux de cholesterol sanguin par l'utilisation de cette combinaison
|
CA2007641A1
(fr)
*
|
1989-02-01 |
1990-08-01 |
Donald S. Karanewsky |
Combinaison d'un inhibiteur de squalene synthetase et d'autres types d'agents reducteurs du cholesterol sanguin et methode pour abaisser le taux de cholesterol sanguin en employant une telle combinaison
|
CA2016467A1
(fr)
*
|
1989-06-05 |
1990-12-05 |
Martin Eisman |
Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
|
CA2018470A1
(fr)
*
|
1989-07-17 |
1991-01-17 |
Scott Adams Biller |
Inhibiteurs de la synthetase de la squalene contenant du soufre, et methode pour ceux-ci
|
US5055487A
(en)
*
|
1990-03-21 |
1991-10-08 |
Merck & Co., Inc. |
Novel anti-fungal compounds
|
US5132320A
(en)
*
|
1990-03-21 |
1992-07-21 |
Merck & Co., Inc. |
Squalene synthetase inhibitors
|
IL97251A0
(en)
*
|
1990-03-21 |
1992-05-25 |
Merck & Co Inc |
Antihypercholesterolemic 2,8-dioxabicyclo(3,2,1)octane derivatives,their preparation and pharmaceutical compositions containing them
|
US5096923A
(en)
*
|
1990-03-21 |
1992-03-17 |
Merck & Co., Inc. |
Novel squalene synthetase inhibitors
|
US6630502B2
(en)
|
1990-05-15 |
2003-10-07 |
E.R. Squibb & Sons, Inc. |
Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
|
US5298497A
(en)
*
|
1990-05-15 |
1994-03-29 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of hypertension employing a cholesterol lowering drug
|
US5102907A
(en)
*
|
1990-09-13 |
1992-04-07 |
Merck & Co., Inc. |
Novel squalene synthetase inhibitors
|
US5026554A
(en)
*
|
1990-09-13 |
1991-06-25 |
Merck & Co., Inc. |
Method of inhibiting fungal growth using squalene synthetase inhibitors
|
CA2067974A1
(fr)
*
|
1991-05-13 |
1992-11-14 |
Scott A. Biller |
Methode pour abaisser le taux de cholesterol grace a un phosphonomethylphosphinate, inhibiteur de la squalene synthetase
|
US5364948A
(en)
*
|
1991-08-02 |
1994-11-15 |
Merck & Co., Inc. |
Biologically active compounds isolated from aerobic fermentation of Trichoderma viride
|
EP0526936A3
(en)
|
1991-08-02 |
1993-05-05 |
Merck & Co. Inc. |
Cholesterol-lowering agents
|
JPH05239075A
(ja)
*
|
1991-08-27 |
1993-09-17 |
Eisai Co Ltd |
含リンイソプレノイド誘導体
|
US5298655A
(en)
*
|
1991-09-27 |
1994-03-29 |
Merck & Co., Inc. |
Farnesyl pyrophosphate analogs
|
DK0540782T3
(da)
*
|
1991-10-07 |
1999-11-01 |
Tno |
Anvendelse af polyisoprenylpyrophosphatanaloger til inhibering af proteinisoprenylering
|
ATE126059T1
(de)
*
|
1991-10-11 |
1995-08-15 |
Squibb & Sons Inc |
Verwendung von farnesyl-protein transferaseinhibitoren zur herstellung eines arzneimittels zur blockierung von durch ras- oncogenen hervorgerufenen neoplastischen transformationen von zellen.
|
EP0541037A3
(en)
*
|
1991-11-06 |
1997-02-26 |
Takeda Chemical Industries Ltd |
Squalene synthetase inhibitory composition and use thereof
|
US5200554A
(en)
*
|
1992-01-21 |
1993-04-06 |
Nasman Jan Anders H |
Bisphosphonic acid derivatives and their use
|
US5278153A
(en)
*
|
1992-05-18 |
1994-01-11 |
E. R. Squibb & Sons, Inc. |
Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method
|
US5283256A
(en)
*
|
1992-07-22 |
1994-02-01 |
Merck & Co., Inc. |
Cholesterol-lowering agents
|
US5254544A
(en)
*
|
1992-09-25 |
1993-10-19 |
E. R. Squibb & Sons, Inc. |
Hydroxyphosphinyl phosphonate squalene synthetase inhibitors and method
|
US5332728A
(en)
*
|
1992-11-23 |
1994-07-26 |
Bristol-Myers Squibb Company |
Method for treating a fungal infection
|
US5362752A
(en)
*
|
1993-05-17 |
1994-11-08 |
Merck & Co., Inc. |
Chemical compounds
|
US5712261A
(en)
*
|
1993-10-04 |
1998-01-27 |
Magnin; David R. |
Method for preventing or treating hypertriglyceridemia
|
IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
US5574025A
(en)
*
|
1994-10-26 |
1996-11-12 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferases
|
US6313127B1
(en)
|
1996-02-02 |
2001-11-06 |
Zeneca Limited |
Heterocyclic compounds useful as pharmaceutical agents
|
US5843983A
(en)
|
1996-02-15 |
1998-12-01 |
Sankyo Company, Limited |
Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use
|
US20020086380A1
(en)
*
|
1996-03-29 |
2002-07-04 |
Francis X. Cunningham Jr |
Genes encoding epsilon lycopene cyclase and method for producing bicyclic carotene
|
BR9711135A
(pt)
*
|
1996-08-14 |
1999-08-17 |
Zeneca Ltd |
Composto composi-Æo farmac-utica utiliza-Æo de um composto e processos para prepara-Æo de um composto e para inibi-Æo de Äxido-equaleno ciclase num animal de sangue quente requerendo um tal tratamento
|
UA56197C2
(uk)
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Гетероциклічні похідні
|
US6440972B1
(en)
|
1997-02-13 |
2002-08-27 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
DK0966462T3
(da)
|
1997-02-13 |
2003-09-22 |
Astrazeneca Ab |
Heterocykliske forbindelser, der er egnede som oxidosqualencyklaseinhibitorer
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
EP2305825B1
(fr)
*
|
1998-07-06 |
2015-01-14 |
DCV Inc. doing business as Bio-Technical Resourses |
Procédé pour la production de vitamines
|
WO2000001650A1
(fr)
|
1998-07-06 |
2000-01-13 |
Dcv, Inc. Doing Business As Bio-Technical Resources |
Procede de production de vitamines
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
DE10030375A1
(de)
*
|
2000-06-21 |
2002-01-03 |
Bayer Ag |
Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
|
US20040249219A1
(en)
*
|
2000-07-05 |
2004-12-09 |
Saucy Gabriel G. |
Method of making teprenone
|
AU2002254567B2
(en)
|
2001-04-11 |
2007-10-11 |
Bristol-Myers Squibb Company |
Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
EP1572892A4
(fr)
*
|
2001-10-18 |
2007-08-22 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
US6984645B2
(en)
*
|
2001-11-16 |
2006-01-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
AU2003225305A1
(en)
|
2002-05-08 |
2003-11-11 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
CN100471047C
(zh)
*
|
2002-05-14 |
2009-03-18 |
西门子公司 |
用于产生发射信号的方法
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
ATE469645T1
(de)
*
|
2002-10-23 |
2010-06-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
WO2004066929A2
(fr)
*
|
2003-01-24 |
2004-08-12 |
Bristol-Myers Squibb Company |
Cycloalkyle contenant des ligands anilide pour le recepteur des hormones thyroidiennes
|
WO2004085448A2
(fr)
*
|
2003-03-19 |
2004-10-07 |
Genzyme Corporation |
Inhibiteurs du transport de phosphate comprenant un groupe phosphinyl-phosphonate insature
|
US7557143B2
(en)
*
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
PT1689757E
(pt)
*
|
2003-11-12 |
2014-12-09 |
Sino Med Internat Alliance Inc |
Compostos heterocíclicos de ácido borónico
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
SI1725234T1
(sl)
|
2004-03-05 |
2013-04-30 |
The Trustees Of The University Of Pennsylvania |
Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
CA2573848A1
(fr)
*
|
2004-07-12 |
2006-02-16 |
Phenomix Corporation |
Composes cyano contraints
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
CA2574593C
(fr)
|
2004-07-27 |
2016-07-05 |
The Regents Of The University Of California |
Cellules hotes genetiquement modifiees et utilisation de celles-ci pour produire des composes isoprenoides
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7314882B2
(en)
*
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7368458B2
(en)
*
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7361766B2
(en)
|
2005-01-12 |
2008-04-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
EP1846410B1
(fr)
*
|
2005-02-10 |
2009-01-21 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones utilisees comme modulateurs de la 5ht
|
EP1879881A2
(fr)
|
2005-04-14 |
2008-01-23 |
Bristol-Myers Squibb Company |
Inhibiteurs de la 11-beta hydroxysteroide deshydrogenase de type i
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
AU2006249869A1
(en)
*
|
2005-05-26 |
2006-11-30 |
Bristol-Myers Squibb Company |
N-terminally modified GLP-1 receptor modulators
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
TW200726765A
(en)
*
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
TWI373329B
(en)
*
|
2005-07-26 |
2012-10-01 |
Colgate Palmolive Co |
Toothbrush
|
KR20080034171A
(ko)
*
|
2005-07-28 |
2008-04-18 |
브리스톨-마이어스 스큅 컴퍼니 |
세로토닌 수용체 효능제 및 길항제로서의 치환된테트라히드로-1h-피리도[4,3,b]인돌
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
EP1951224A2
(fr)
*
|
2005-10-18 |
2008-08-06 |
Aegerion Pharmaceuticals |
Methodes permettant de traiter les troubles associes a l'hyperlipidemie chez un mammifere
|
US8618115B2
(en)
|
2005-10-26 |
2013-12-31 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
|
WO2007053819A2
(fr)
|
2005-10-31 |
2007-05-10 |
Bristol-Myers Squibb Company |
Inhibiteurs à base d'amide et de bêta-amino de pyrrolidinyle de la dipeptidyl peptidase iv et procédés
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
EP1976873A2
(fr)
*
|
2006-01-11 |
2008-10-08 |
Brystol-Myers Squibb Company |
Modulateurs de peptides 1 de type glucagon humain et leur utilisation pour traiter le diabète et des états associés
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
US8288339B2
(en)
|
2006-04-20 |
2012-10-16 |
Amgen Inc. |
GLP-1 compounds
|
JP5230613B2
(ja)
|
2006-05-23 |
2013-07-10 |
テラコス・インコーポレイテッド |
グルコース輸送体阻害剤およびその使用方法
|
WO2007139589A1
(fr)
*
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Modulateurs des récepteurs de glp-1 à libération prolongée
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
WO2008057862A2
(fr)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
Modulateurs de récepteur de glucocorticoïde, d'activité ap-1 et/ou nf-κb, et leur utilisation
|
US20080161279A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Wisler Gerald L |
Methods of Treating Obesity
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
CN101754972A
(zh)
*
|
2007-05-18 |
2010-06-23 |
百时美施贵宝公司 |
Sglt2抑制剂的晶体结构及其制备方法
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
WO2009018065A2
(fr)
*
|
2007-07-27 |
2009-02-05 |
Bristol-Myers Squibb Company |
Nouveaux activateurs de glucokinase et procédés pour les utiliser
|
BRPI0815708B8
(pt)
|
2007-08-23 |
2021-05-25 |
Theracos Sub Llc |
composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
AU2009270936B2
(en)
*
|
2008-07-15 |
2014-12-18 |
Theracos, Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
US20100256153A1
(en)
|
2009-03-27 |
2010-10-07 |
Bristol-Myers Squibb Company |
Methods for preventing or reducing risk of mortality
|
LT2498758T
(lt)
|
2009-11-13 |
2018-11-26 |
Astrazeneca Ab |
Dvisluoksnės tabletės formuluotės
|
AU2010319438B2
(en)
|
2009-11-13 |
2015-05-21 |
Astrazeneca Uk Limited |
Reduced mass metformin formulations
|
PL2498759T3
(pl)
|
2009-11-13 |
2019-03-29 |
Astrazeneca Ab |
Formulacje tabletek o natychmiastowym uwalnianiu
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
EP2558461B1
(fr)
|
2010-04-14 |
2015-12-02 |
Bristol-Myers Squibb Company |
Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs
|
WO2011153712A1
(fr)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
|
EP2590634B1
(fr)
|
2010-07-09 |
2016-03-09 |
BHV Pharma, Inc. |
Système d'administration à libération immédiate/retardée en combinaison pour des médicaments à courte demi-vie comprenant de la rémogliflozine
|
EP2600716A4
(fr)
|
2010-08-03 |
2014-02-19 |
Beth Israel Hospital |
Procédés et compositions pour le traitement de troubles métaboliques
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
SG11201503923XA
(en)
|
2012-11-20 |
2015-06-29 |
Lexicon Pharmaceuticals Inc |
Inhibitors of sodium glucose cotransporter 1
|
WO2015027021A1
(fr)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Dérivés imide et acylurée utilisés comme modulateurs du récepteur de glucocorticoïdes
|
CA2982427A1
(fr)
|
2015-04-30 |
2016-11-03 |
President And Fellows Of Harvard College |
Anticorps anti-ap2 et agents de liaison a l'antigene utilisables en vue du traitement d'affections metaboliques
|
KR20210034039A
(ko)
|
2018-07-19 |
2021-03-29 |
아스트라제네카 아베 |
다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물
|
WO2020068661A1
(fr)
|
2018-09-26 |
2020-04-02 |
Lexicon Pharmaceuticals, Inc. |
Formes cristallines de n-(1 -((2-(diméthylamino)éthyl)amino)-2-m éthyl-1 -oopropan-2-yl)-4-(4-(2-méthyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(méthylthio)tétrahydro-2h-pyran-2-yl)benzyl) phényl)butanamide et procédés de synthèse associés
|